Eli Lilly and Company (NYSE:LLY) Updates FY 2024 Earnings Guidance

Eli Lilly and Company (NYSE:LLY) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 13.500-14.000 for the period, compared to the consensus estimate of 12.500. The company issued revenue guidance of $42.4 billion-$43.6 billion, compared to the consensus revenue estimate of $41.4 billion.

Eli Lilly and Company Stock Down 1.8 %

Shares of NYSE LLY traded down $14.18 during midday trading on Thursday, reaching $762.57. The company’s stock had a trading volume of 1,186,274 shares, compared to its average volume of 3,044,902. Eli Lilly and Company has a fifty-two week low of $414.31 and a fifty-two week high of $800.78. The stock has a 50 day simple moving average of $762.03 and a 200-day simple moving average of $669.96. The stock has a market capitalization of $724.56 billion, a price-to-earnings ratio of 113.06, a PEG ratio of 1.58 and a beta of 0.37. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 59.28%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same period in the previous year, the business earned $1.62 EPS. The company’s revenue was up 26.0% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 13.5 earnings per share for the current year.

Analysts Set New Price Targets

LLY has been the subject of a number of analyst reports. TheStreet upgraded Eli Lilly and Company from a c+ rating to a b rating in a research note on Friday, March 8th. Truist Financial increased their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the company a buy rating in a report on Wednesday. Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an overweight rating in a report on Tuesday, February 6th. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an overweight rating in a research note on Friday, February 16th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an overweight rating in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average target price of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.